7ACD648E-76FD-4C83-86AA-51F581A0B09C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 40.37450722733246
- age_years
- 25
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0915FD2C-0C30-4437-83BA-DFBDF3CDBC61 | — | — | 0.882 |
| 2 | 24F914FE-3DF0-4286-9231-9D525A777306 | — | — | 0.881 |
| 3 | 51708DA2-649D-4817-BB26-7FD153C65965 | — | — | 0.879 |
| 4 | 7779D220-647F-4D6C-890B-022208B51F57 | — | — | 0.870 |
| 5 | SRR934870 | — | — | 0.861 |
| 6 | 53BA607F-7939-40D9-BEFA-DC4ABDC7630B | — | — | 0.861 |
| 7 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.860 |
| 8 | SRR934724 | — | — | 0.856 |
| 9 | 17C2A071-0813-4992-96D8-5C432D6EC9E6 | — | — | 0.854 |
| 10 | E81FA8B7-3FFE-4F73-94AF-0B5257D7F81A | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.477 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.376 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.335 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.324 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.313 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.307 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.247 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.183 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.168 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.168 | Idelalisib | — uncovered |
| PEROXISOME | 0.147 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.115 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.085 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.075 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.067 | Inavolisib | — uncovered |